Dernières nouvelles pour Femto Technologies (NASDAQ:FMTO) Stock

Femto Technologies

Femto Technologies Inc is an integrated software company. It owns and markets Benefit CRM, a proprietary customer relationship management CRM software product enabling small and medium sized businesses to optimize their day to day business activities such as sales management, personnel management, marketing, call center activities, and asset management.

Femto Technologies Inc

Workiva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WK#NYSE">WK</a>) reported quarterly earnings of $0.33 per share which met the analyst consensus estimate. This is a 10 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $199.899 million which beat the analyst consensus estimate of $195.297 million by 2.36 percent. This is a 19.95 percent increase over sales of $166.653 million the same period last year.

Earnings

Earnings Beats

News

Workiva Q4 2024 Adj. EPS $0.33, Inline, Sales $199.899M Beat $195.297M Estimate

Skyward Specialty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.75 by 6.67 percent. This is a 31.15 percent increase over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $304.40 million which beat the analyst consensus estimate of $295.80 million by 2.91 percent. This is a 35.33 percent increase over sales of $224.93 million the same period last year.

SKWD

Skyward Specialty Q4 2024 Adj EPS $0.80 Beats $0.75 Estimate, Sales $304.40M Beat $295.80M Estimate

Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.15 by 26.67 percent. This is a 850 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $107.09 million which beat the analyst consensus estimate of $106.76 million by 0.31 percent. This is a 14.43 percent increase over sales of $93.58 million the same period last year.

Sprout Social Q4 Adj $0.19 Beats $0.15 Estimate, Sales $107.09M Beat $106.76M Estimate

Guidance

ZoomInfo Sees Q1 2025 Revenue $294M-$297M Vs $292.408M Estimate; Sees Adj. EPS $0.22-$0.23 Vs $0.22 Est

Safety Insurance Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFT#NASDAQ">SAFT</a>) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $1.17 by 19.66 percent. This is a 213.33 percent increase over earnings of $0.30 per share from the same period last year. The company reported $269.050 million in sales this quarter. This is a 19.03 percent increase over sales of $226.029 million the same period last year.

Earnings Misses

SAFT

Safety Insurance Group Q4 2024 Adj. EPS $0.94 Misses $1.17 Estimate, Sales $269.050M Up From $226.029M YoY

Playa Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLYA#NASDAQ">PLYA</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.04 by 100 percent. This is a 100 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $218.94 million which beat the analyst consensus estimate of $212.98 million by 2.80 percent. This is a 9.72 percent decrease over sales of $242.52 million the same period last year.

PLYA

Playa Hotels & Resorts Q4 Adj $0.08 Beats $0.04 Estimate, Sales $218.94M Beat $212.98M Estimate

Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.35 by 2.86 percent. The company reported quarterly sales of $1.296 billion which missed the analyst consensus estimate of $1.300 billion by 0.34 percent. This is a 15.41 percent increase over sales of $1.123 billion the same period last year.

Permian Resources Q4 2024 Adj. EPS $0.36 Beats $0.35 Estimate, Sales $1.296B Miss $1.300B Estimate

RBC Capital Markets has initiated coverage on Insmed Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), citing brensocatib&#8217;s launch momentum.
In February, the FDA accepted the company&#8217;s New Drug Application (NDA) for brensocatib for patients with bronchiectasis and granted the application Priority Review with a Prescription Drug User Fee Act target action date of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43843781/insmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-update" rel="noreferrer noopener">August 12, 2025</a>.
If approved, Insmed expects brensocatib to launch in the U.S. in the third quarter.
The FDA also informed the company that it does not currently plan to hold an advisory committee meeting to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43910133/insmed-announces-that-fda-does-not-currently-plan-to-hold-advisory-committee-meeting-to-discuss-ne" rel="noreferrer noopener">discuss the New Drug Application</a>.
RBC Capital analyst Leonid Timashev says brensocatib has potential for a $6.5 billion opportunity in bronchiectasis and a rapid launch, &#8220;making Insmed an attractive midcap biotech.&#8221;
RBC has initiated with an Outperform rating with a <a target="_blank" href="https://www.benzinga.com/quote/INSM/analyst-ratings" rel="noreferrer noopener">price forecast of $100</a>.
The RBC analyst expects a high likelihood of approval for the bronchiectasis treatment with a favorable label, paving the way for a strong launch. Feedback from key opinion leaders (KOLs) and the company&#8217;s prelaunch efforts and education suggests a strong willingness to prescribe. Around 50% or more of eligible patients could receive brensocatib after its mid-2025 launch.
While insurance coverage and reaching moderate patients may pose early challenges, frequent patient visits, positive initial experiences, and being the only approved treatment should drive adoption and coverage. Past respiratory drug launches (asthma, COPD) have performed well.
RBC says Arikayce, an antibiotic, continues to generate steady revenue and has strong potential for a major label expansion if the Phase 3 ENCORE study delivers positive results in 2026. Leonid Timashev estimates peak sales could reach $1 billion, valuing Arikayce at up to $25 per share.
Last week, Insmed reported a fourth-quarter loss of $1.32 per share, missing the consensus loss of $1.17. Sales reached $104.4 million, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $101.79 million</a>.
Insmed anticipates full-year 2025 global Arikayce revenue of $405 million-$425 million, up 11%-17% year over year.
Price Action: INSM stock closed down by 3.17% to $77.49 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43945751/huawei-boosts-ai-chip-production-despite-taiwan-semi-and-asml-ban-aims-to-challenge-nvidia-in-china" target="_blank" rel="noreferrer noopener">Huawei Boosts AI Chip Production Despite Taiwan Semi And ASML Ban, Aims to Challenge Nvidia In China</a></li>
</ul>
Image via Shutterstock

Analyst Color

Biotech

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

INSM

Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says

INTU

Intuit Sees FY25 Revenue $18.16B-$18.347B Vs 20.527B Estimate; Sees Adj. EPS $19.16-$19.36 Vs $22.13 Estimate

WBTN

WEBTOON Entertainment Sees Q1 Revenue $318M-$328M Vs $369.1M Est.

SPXC

SPX Techs Sees FY25 Adj. EPS $6.00-$6.25 Vs $6.12 Est.

ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.22 by 18.18 percent. This is unchanged from the same period last year. The company reported quarterly sales of $309.10 million which beat the analyst consensus estimate of $297.63 million by 3.85 percent. This is a 2.31 percent decrease over sales of $316.40 million the same period last year.

ZoomInfo Technologies Q4 2024 Adj EPS $0.26 Beats $0.22 Estimate, Sales $309.10M Beat $297.63M Estimate

SPX Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) reported quarterly earnings of $1.51 per share which met the analyst consensus estimate. This is a 20.8 percent increase over earnings of $1.25 per share from the same period last year. The company reported quarterly sales of $533.700 million which beat the analyst consensus estimate of $532.715 million by 0.18 percent. This is a 13.70 percent increase over sales of $469.400 million the same period last year.

SPX Techs Q4 2024 Adj. EPS $1.51, Inline, Sales $533.700M Beat $532.715M Estimate

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $1.11 by 0.9 percent. This is a 2.75 percent increase over earnings of $1.09 per share from the same period last year. The company reported quarterly sales of $85.75 million which beat the analyst consensus estimate of $82.67 million by 3.72 percent. This is a 7.91 percent increase over sales of $79.47 million the same period last year.

National Health Investors Q4 2024 FFO $1.12 Beats $1.11 Estimate, Sales $85.75M Beat $82.67M Estimate

Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.34) by 91.18 percent. The company reported quarterly sales of $352.800 million which missed the analyst consensus estimate of $354.425 million by 0.46 percent.

Webtoon Entertainment Q4 2024 Adj. EPS $(0.03) Beats $(0.34) Estimate, Sales $352.800M Miss $354.425M Estimate

Extra Space Storage Sees 2025 Core FFO $8-$8.30

Light &amp; Wonder (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) reported quarterly earnings of $1.42 per share which beat the analyst consensus estimate of $0.95 by 49.47 percent. The company reported quarterly sales of $797.000 million which missed the analyst consensus estimate of $797.867 million by 0.11 percent. This is a 3.51 percent increase over sales of $770.000 million the same period last year.

Light & Wonder Q4 2024 Adj. EPS $1.42 Beats $0.95 Estimate, Sales $797.000M Miss $797.867M Estimate

Extra Space Storage Q4 2024 FFO $2.03 Beats $2.02 Estimate, Sales $707.234M Miss $759.594M Estimate

IPAR

Interparfums Reaffirms FY25 Guidance And Sees EPS $5.35 Vs $5.31 Est.; Revenue $1.51B Vs $1.503 Est.

Boston Beer Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) reported quarterly losses of $(1.68) per share which missed the analyst consensus estimate of $(1.29) by 30.23 percent. The company reported quarterly sales of $402.30 million which beat the analyst consensus estimate of $389.18 million by 3.37 percent. This is a 2.18 percent increase over sales of $393.72 million the same period last year.

Comments

Femto Technologies

Actualités

Dernières nouvelles pour Femto Technologies (NASDAQ:FMTO) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL